sellas life sciences share price

SLS SELLAS or the Company a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications today reported its financial results for the quarter ended March 31 2022 and. NEW YORK May 12 2022 GLOBE NEWSWIRE -- SELLAS Life Sciences Group Inc.

Sellas Life Sciences Group Inc Sls Stock 10 Year History

Get Sellas Life Sciences Group Inc SLSNASDAQ real-time stock quotes news price and financial information from CNBC.

. NEW YORK May 12 2022 GLOBE NEWSWIRE -- SELLAS Life Sciences Group Inc. SELLAS Life Sciences Group Inc. 4 brokers have issued 12-month price objectives for SELLAS Life Sciences Groups stock.

Get the latest SELLAS Life Sciences Group stock price and detailed information including SLS news historical charts and realtime prices. SLSNAQ price moved over -232 to 295 Apr 25 2022 Key statistics On Friday Sellas Life Sciences Group Inc SLSNAQ closed at 272 543 above its 52-week low of 258 set on Apr 28 2022. The chart has 1 X axis displaying Time.

07 2021 GLOBE NEWSWIRE -- SELLAS Life Sciences Group Inc. SLS is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. SLS SELLAS Life Sciences Group Inc Stock Price and Discussion Stocktwits.

Common Stock SLS Stock Quotes - Nasdaq offers stock quotes market activity data for US and global markets. SLS stock price news historical charts analyst ratings and financial information from WSJ. Price and volume over 1Y period.

Their forecasts range from 1400 to 2100. Net loss was 167 million for the first quarter of 2022 or a basic and diluted loss per share of 105 as compared to a net loss of 24 million for. The Companys lead product candidate galinpepimut-S GPS is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center that.

On November 28 2006 we changed our name to RXi Pharmaceuticals Corporation and began operations January 2007. NEW YORK May 12 2022 GLOBE NEWSWIRE -- SELLAS Life Sciences Group Inc. 102 rows SELLAS Life Sciences Group Inc.

The average twelve-month price target for SELLAS Life Sciences Group is 1788 with a high price target of 2100 and a low price target of 1600. This suggests a possible upside of 6533 from the stocks current price. As of last trade Sellas Life Sciences Group Inc RXK3HAM traded at 268 452 above its 52-week low of 257 set on May 02 2022.

SELLAS Life Sciences Announces Pricing of 250 Million Underwritten Public Offering. View as data table SELLAS Life Sciences Group Inc. By 3D Medicines and licensing revenue during the first quarter of 2021 was related to the initial transaction price of the license agreement with 3D Medicines which was recognized over a period of time.

Stock analysis for SELLAS Life Sciences Group Inc RXK3Frankfurt including stock price stock chart company news key statistics fundamentals and company profile. SELLAS Life Sciences Group Inc reported its financial results for the quarter ended March 31 2022 and provided a business update. Sellas Life Sciences Group Inc.

SELLAS Life Sciences Group Inc NASDAQ Updated Apr 27 2022 1135 PM. SELLAS Life Sciences Group Inc. SLS NasdaqCM - NasdaqCM Real Time Price.

View the latest SELLAS Life Sciences Group Inc. Stock analysis for SELLAS Life Sciences Group Inc SLSNASDAQ CM including stock price stock chart company news key statistics fundamentals and company profile. Day Range 33500 - 34700.

Maxim Group Adjusts SELLAS Life Sciences Group Price Target to 12 From 21 Maintains. SLS SELLAS or the Company a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications today reported its financial results for the quarter ended March 31 2022 and. May 2 45143 PM GMT-4 USD NASDAQ Disclaimer.

NEW YORK March 31 2022 GLOBE NEWSWIRE -- SELLAS Life. SELLAS Life Sciences Announces Pricing of 250 Million Underwritten Public Offering GlobeNewswire Inc. Thu Mar 31 2022 903 PM 1 month ago.

According to the issued ratings of 4 analysts in the last year the consensus rating for SELLAS Life Sciences Group stock is Buy based on the current 4 buy ratings for SLS. 52 Week Range 32200 - 150789. SELLAS Life Sciences Group Inc.

Free Cash Flow per Share - - - - - Book Value per. Is a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications. On average they anticipate SELLAS Life Sciences Groups share price to reach 1725 in the next year.

Chart represents SELLAS Life Sciences Group Inc.

Sellas Life Sciences Sls Market Capitalization